

Global DLL3 Targeted Therapies Market Opportunities & Clinical Trials Insight 2024

<https://marketpublishers.com/r/GCCFA162F962EN.html>

Date: January 2024

Pages: 140

Price: US\$ 3,300.00 (Single User License)

ID: GCCFA162F962EN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Global DLL3 Targeted Therapies Market Opportunities & Clinical Trials Insight 2024
Report Finding & Highlights:

Role of DLL3 As Diagnostic & Prognostic Markers

DLL3 Targeting Approaches, Mechanism & Commercial Aspects

Insight On Current & Potential DLL3 Targeted Therapies Proprietary Platforms:
> 10 Platform

DLL3 Targeted Drugs Clinical Trials Insight By Company, Indication & Phase: >
15 Drugs

Global DLL3 Targeted Therapies Research & Market Trends By Indication

DLL3 Targeted Therapies Research & Market Trends by Region

Insight On Companies Involved In R&D Of DLL3 Targeted Therapies: 14
Companies

In recent years, the discovery of Delta Like Ligand 3 (DLL3) as a therapeutic cancer target has emerged as key defining moment in the targeted therapy landscape. Understanding DLL3's role and pathways in both non cancer and cancer scenarios has

shed light on its potential as a groundbreaking treatment option. DLL3, a transmembrane protein previously known for its role in non-cancerous cellular processes, has emerged as a promising cancer treatment target due to its overexpression in a variety of malignancies, particularly neuroendocrine cancers such as small-cell lung cancer, bladder cancer, and gastroenteropancreatic tumors.

Stemcentrx, now a subsidiary of AbbVie, led the development of Rovalpituzumab tesirine (Rova-T), which was a pioneering endeavor in the field of DLL3 targeted therapies. Rova-T, an antibody-drug combination containing a DLL3-targeting antibody coupled to a cytotoxic chemical, was designed to take advantage of the specific overexpression of DLL3 in cancer cells. Despite initial enthusiasm, the cessation of Rova-T in later-phase clinical trials due to negative results presented both challenges and lessons.

Despite being discontinued in later stage clinical studies, Rova-T has left an indelible mark on the landscape of DLL3 targeted therapeutics, acting as a catalyst for the discovery and development of novel pharmacological classes. Following Rova-T's journey, its legacy lives on with Rovalpituzumab being the primary antibody component in a variety of antibody-drug conjugates, indicating a paradigm change in cancer therapy. These conjugates, which carry a variety of payloads such as radionuclides, photoabsorbers, and photosensitizers, have emerged as viable candidates in ongoing scientific research and clinical trials.

By combining Rova-T's DLL3-targeting antibody Rovalpituzumab into these innovative conjugates, scientists have leveraged the potential of diverse payloads to enhance the precision and efficacy of cancer treatment. Incorporating radionuclides, providing tailored radiation therapy, and using photoabsorbers and photosensitizers for photodynamic therapy are all exciting options that have shown great promise in preclinical and early clinical trials.

The dynamic evolution of DLL3 targeted therapies is characterized by a wide range of candidates in clinical trials, extending far beyond Rovalpituzumab conjugates. The current landscape encompasses a wide range of novel approaches, from bispecific and trispecific antibodies to cutting-edge cell therapies like CAR T and CAR NK cell therapies. While many of these candidates are still in early stages of development, significant exceptions, like as Amgen's Tarlatamab, have advanced to phase 3 trials. Tarlatamab's advancement to this pivotal stage not only reflects the accelerated pace of research in DLL3 targeted therapies, but also establishes a significant benchmark for the field, indicating a critical step toward the potential translation of these novel

therapeutic modalities from experimental concepts to clinically validated treatments.

Tarlatamab has reached key milestones on its extraordinary path, first receiving orphan drug designation for small cell lung cancer (SCLC) in 2018 and then breakthrough therapy designation in October 2023. These accolades highlight its potential as a novel therapeutic approach for a cancer with few treatment alternatives. More recently, in December 2023, it was granted the FDA Priority Review; the FDA Target Action Date for Tarlatamab is June 12, 2024, putting this innovative therapy on the verge of making history as the first BiTE® (bispecific T cell engager) therapy for a major solid tumor and potentially clinching the coveted title of the first FDA-approved DLL3 targeted therapy.

The culmination of these designations and impending regulatory decisions not only demonstrates Tarlatamab's clinical promise, but also emphasizes its critical role in shaping the future landscape of cancer treatment, particularly in the context of DLL3 targeted therapies, as it approaches potential approval and clinical integration.

Several major pharmaceutical companies, including Roche (via Chugai Pharmaceutical), Boehringer Ingelheim, and Novartis, are actively working on DLL3 targeted therapies, demonstrating the significant interest and potential in this therapeutic area. Partnerships and license agreements highlight the field's collaborative character, with significant examples include the current collaboration between Boehringer Ingelheim and Oxford BioTherapeutics, as well as newer collaborations with Novartis and Legend, MediLink Therapeutics, and Zai Lab.

The DLL3 targeted therapeutic market is rapidly evolving, with Tarlatamab at the forefront. Growth is being driven by a better knowledge of the role of DLL3 in cancer, ongoing research and development initiatives, and strategic partnerships that promote innovation. The future contains enormous possibilities and prospects for stakeholders in this sector, including the promise of novel therapy modalities, improved patient outcomes, and a transformative impact on the cancer treatment landscape. As the development of DLL3 targeted therapies progresses, it becomes obvious that collaboration, ingenuity, and tenacity will continue to influence the future of cancer therapies domain.

Contents

1. RESEARCH METHODOLOGY

2. INTRODUCTION TO DLL3 TARGETED THERAPIES

2.1 Overview

2.2 History & Evolution of DLL3 Targeted Therapies

3. ROLE OF DLL3 AS DIAGNOSTIC & PROGNOSTIC MARKERS

3.1 Diagnostic Biomarker

3.2 Prognostic Biomarker

4. DLL3 TARGETING APPROACHES, MECHANISM & COMMERCIAL ASPECTS

4.1 Antibody Drug Conjugates

4.2 Antibodies

4.3 Cell therapies

4.4 Antibody Radionuclide Conjugates

4.5 Antibody Photoabsorber/Photosensitizer Conjugate

5. GLOBAL DLL3 TARGETED THERAPIES RESEARCH & MARKET TRENDS BY INDICATION

5.1 Small Cell Lung Cancer

5.2 Large Cell Neuroendocrine Cancer

5.3 Neuroendocrine Prostate Cancer

5.4 Gastroenteropancreatic Neuroendocrine Tumors

5.5 Glioma

6. DLL3 TARGETED THERAPIES PROPRIETARY PLATFORMS

6.1 Platforms Used To Develop DLL3 Targeted Therapies

6.2 Potential Platforms for DLL3 Targeted Therapies Development

7. GLOBAL DLL3 TARGETED DRUGS CLINICAL TRIALS OVERVIEW

- 7.1 By Company
- 7.2 By Fast Track Status
- 7.3 By Indication
- 7.4 By Location
- 7.5 By Patient Segment
- 7.6 By Phase

8. GLOBAL DLL3 TARGETED DRUGS CLINICAL TRIALS BY COMPANY, INDICATION & PHASE

- 8.1 Research
- 8.2 Preclinical
- 8.3 Phase-I
- 8.4 Phase-I/II
- 8.5 Phase-II
- 8.6 Preregistration

9. DLL3 TARGETED THERAPIES MARKET TRENDS & CLINICAL TRIALS INSIGHTS

- 9.1 Current Market Trends, Developments & Clinical Trials Assessment
- 9.2 Future Commercialization Opportunity

10. DLL3 TARGETED THERAPIES RESEARCH & MARKET TRENDS BY REGION

- 10.1 US
- 10.2 UK
- 10.3 EU
- 10.4 Canada
- 10.5 Australia
- 10.6 China

11. DLL3 TARGETED THERAPIES MARKET DYNAMICS

- 11.1 Favorable Market & Clinical Development Parameters
- 11.2 Challenges & Restraints

12. KEY COMPANIES INVOLVED IN RESEARCH & DEVELOPMENT OF DLL3 TARGETED THERAPIES

- 12.1 Abdera Therapeutics
- 12.2 Allogene Therapeutics
- 12.3 Amgen
- 12.4 Boehringer Ingelheim
- 12.5 Chugai Pharmaceutical
- 12.6 Gensun Biopharma
- 12.7 Harpoon Therapeutics
- 12.8 ImaginAb Inc
- 12.9 Legend Biotech
- 12.10 Molecular Partners
- 12.11 Phanes Therapeutics
- 12.12 Qilu Pharmaceutical
- 12.13 Shanghai Affinity Biopharmaceutical
- 12.14 ZAI Lab

Figure 4-1: Antibody Drug Conjugates - Mechanism Of Action

Figure 4-2: BiTE - Amgen

Figure 4-3: HPN328 - Structure

Figure 4-4: Rova-IR700 - Mechanism

Figure 5-1: DLL3 - Small Cell Lung Cancer

Figure 5-2: DeLLphi-301 Phase 2 Study – Initiation & Completion Year

Figure 5-3: DeLLphi-304 Phase 2 Study – Initiation & Completion Year

Figure 5-4: DAREON™-5 Phase 2 Study – Initiation & Completion Year

Figure 5-5: PT217X1101 Phase 1 Study – Initiation & Completion Year

Figure 5-6: HPN328 Phase 1 Study – Initiation & Completion Year

Figure 5-7: LB2102-1001 Phase 1 Study – Initiation & Completion Year

Figure 5-8: NCT05507593 Phase 1 Study – Initiation & Completion Year

Figure 5-9: DLL3 – Large Cell Neuroendocrine Cancer

Figure 6-1: T-Charge Platform - Features

Figure 6-2: BiTE® Antibody Construct

Figure 6-3: TMALIN – ADC Advantages

Figure 6-4: TMALIN – ADC Structure

Figure 6-5: TriTAC - T-Cell Engagers Structure

Figure 6-6: TriTAC - Advantages

Figure 6-7: PACbody™ Platform

Figure 6-8: ATACCbody™ Platform

Figure 6-9: SPECpair™ Platform

Figure 6-10: ROVER Platform - Process

Figure 6-11: RPT - Advantages

Figure 6-12: Dual-Ig Technology – Antibody Structure & Mechanism

Figure 6-13: AlloCAR T - Process

Figure 6-14: AlloCAR T - Features

Figure 6-15: Alluminox™ Platform - Drug Structure

Figure 6-16: Rakuten Medical - Photoimmunotherapy Process

Figure 7-1: Global - DLL3 Targeted Drugs Clinical Trials By Company (Number), 2024

Figure 7-2: Global - DLL3 Targeted Drugs Clinical Trials By Fast Track Status (Number), 2024

Figure 7-3: Global - DLL3 Targeted Drugs Clinical Trials By Indication (Number), 2024

Figure 7-4: Global - DLL3 Targeted Drugs Clinical Trials By Location (Number), 2024

Figure 7-5: Global - DLL3 Targeted Drugs Clinical Trials By Patient Segment (Number), 2024

Figure 7-6: Global - DLL3 Targeted Drugs Clinical Trials By Phase (Number), 2024

Figure 11-1: DLL3 Targeted Therapies – Market Drivers & Opportunities

Figure 11-2: DLL3 Targeted Therapies – Market Challenges & Restraints

Table 5-1: Large Cell Neuroendocrine Cancer – Candidates In Clinical Trials

Table 5-2: Neuroendocrine Prostate Cancer – Candidates In Clinical Trials

Table 5-3: Gastroenteropancreatic Neuroendocrine Tumors – Candidates In Clinical Trials

Table 5-4: Glioma – Candidates In Clinical Trials

Table 10-1: US – FDA Designated DLL3 Targeted Therapies

I would like to order

Product name: Global DLL3 Targeted Therapies Market Opportunities & Clinical Trials Insight 2024

Product link: <https://marketpublishers.com/r/GCCFA162F962EN.html>

Price: US\$ 3,300.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GCCFA162F962EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970